--- title: A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants nct_id: NCT04474210 overall_status: TERMINATED phase: PHASE1 sponsor: Janssen Research & Development, LLC study_type: INTERVENTIONAL primary_condition: Renal Insufficiency countries: United States canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04474210.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04474210" ct_last_update_post_date: 2021-07-23 last_seen_at: "2026-05-12T06:07:18.988Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants **Official Title:** An Open-Label, Single-Dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-56136379 in Adult Participants **NCT ID:** [NCT04474210](https://clinicaltrials.gov/study/NCT04474210) ## Key Facts - **Status:** TERMINATED - **Why Stopped:** Strategic Decision - **Phase:** PHASE1 - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 1 - **Lead Sponsor:** Janssen Research & Development, LLC - **Conditions:** Renal Insufficiency - **Start Date:** 2020-08-19 - **Completion Date:** 2020-11-30 - **CT.gov Last Update:** 2021-07-23 ## Brief Summary The purpose of this study is to evaluate the pharmacokinetics (PK) of a single oral dose of JNJ-56136379 in adult participants with renal impairment compared with healthy participants with normal renal function. ## Eligibility - **Minimum age:** 18 Years - **Maximum age:** 80 Years - **Sex:** ALL - **Healthy Volunteers:** Yes ``` Inclusion Criteria: \- Body mass index (BMI) (kilograms \[kg\]/height \[m\]\^2) between 18.0 and 38.0 kilogram/meter\^2 (kg/m2) (inclusive), and body weight not less than (\<) 50 kg Participants with normal renal function: * Have normal renal function defined as estimated glomerular filtration rate (eGFR) greater than or equal to (\>=) 90 milliliter/minute computed with the online calculator on the CKD-EPI website by use of the Chronic Kidney Disease Epidemiology Collaboration creatinine clearance (CKD-EPIcr) result * Must have stable renal function as defined as: (a) for participants with impaired renal function: \<20 percent (%) change in serum creatinine concentrations between screening and Day -1; (b) for healthy participants: a change in serum creatinine concentration \<0.2 milligram per deciliter (mg/dL) between screening and Day -1 Participants with renal impairment: * Have an impaired renal function based on eGFR as(eGFR computed with the online calculator on the CKD-EPI website providing eGFR (in mL/min units) by use of the CKD-EPIcr result: (a) eGFR \<90 to 60 mL/minute for participants in Group 3 (mild renal impairment cohort); (b) eGFR 30 to 59 mL/minute for participants in Group 4 (moderate renal impairment cohort); (c) eGFR \<30 mL/minute but not yet on hemodialysis, for participants in Group 1 (severe renal impairment and/or kidney failure); (d) eGFR \<15 mL/minute and on hemodialysis, for participants in Group 5 (kidney failure) * Concomitant medications to treat underlying disease states or medical conditions related to renal impairment are allowed. Participants must be on a stable dose of medication and/or treatment regimen for at least 2 months (3 months for thyroid hormone replacement therapy \[HRT\]) before dosing as well as during the study Exclusion Criteria: \- Individuals who take creatine supplements, have a non-standard muscle mass such as amputation, malnutrition, or muscle wasting; because these factors are not accounted for in the prediction equations for GFR chronic kidney disease epidemiology collaboration (CKD EPI) Participants with normal renal function: * Clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at screening or Day -1, as deemed appropriate by the investigator * Clinically significant abnormal physical examination, vital signs, body temperature, or 12 lead ECG at screening or Day -1, as deemed appropriate by the investigator Participants with renal impairment: * Evidence of clinically apparent concurrent disease based upon complete clinical laboratory testing, full physical examination, or medical history, except for controlled hypertension and those problems directly associated with the primary diagnosis of renal impairment * Any clinically significant laboratory abnormality except abnormalities that may be caused by renal impairment ``` ## Arms - **Part A: Group 1** (EXPERIMENTAL) — Participants with severe renal impairment and/or kidney failure (estimated glomerular filtration rate \[eGFR\] less than \[\<\] 30 milliliter\[mL\]/minute but not yet on hemodialysis) will receive a single oral dose of JNJ-56136379. - **Part A: Group 2** (ACTIVE_COMPARATOR) — Healthy participants with normal renal function (eGFR greater than or equal to \[\>=\] 90 mL/minute), will receive a single oral dose of JNJ-56136379. - **Part B: Group 3 (Optional)** (EXPERIMENTAL) — Participants with mild renal impairment (eGFR: 60 to 89 mL/minute) will receive a single oral dose of JNJ-56136379. - **Part B: Group 4 (Optional)** (EXPERIMENTAL) — Participants with moderate renal impairment (eGFR: 30 to 59 mL/minute) will receive a single oral dose of JNJ-56136379. - **Part B: Group 5 (Optional)** (EXPERIMENTAL) — Participants with kidney failure (eGFR: \<15 mL/minute and on hemodialysis; pharmacokinetic \[PK\] to be evaluated during non-dialysis days) will receive a single oral dose of JNJ-56136379. ## Interventions - **JNJ-56136379** (DRUG) — Participants will receive JNJ-56136379 tablets orally. ## Primary Outcomes - **Maximum Observed Plasma Analyte Concentration (Cmax)** _(time frame: Up to Day 29)_ — Cmax is defined as the maximum observed plasma analyte concentration. - **Time to Reach the Maximum Observed Plasma Analyte Concentration (Tmax)** _(time frame: Up to Day 29)_ — Tmax is defined as the actual sampling time to reach the maximum observed plasma analyte concentration. - **Area Under the Analyte Concentration-time Curve From Time Zero to 24 Hours Postdose (AUC [0-24])** _(time frame: Up to 24 hours postdose)_ — AUC (0-24) is defined as area under the analyte concentration-time curve (AUC) from time 0 to 24 hours postdose, calculated by linear-linear trapezoidal summation. - **Area Under the Analyte Concentration-time Curve From Time Zero to 144 Hours Postdose (AUC [0-144])** _(time frame: Up to 144 hours postdose)_ — AUC (0-144) is defined as AUC from time 0 to 144 hours postdose, calculated by linear-linear trapezoidal summation. - **Area Under the Analyte Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC [0-last])** _(time frame: Up to Day 29)_ — AUC (0-last) is defined as AUC from time 0 to the time of the last measurable (non-below quantification limit \[non-BQL\]) concentration, calculated by linear-linear trapezoidal summation. - **Area Under the Analyte Concentration-time Curve From Time Zero to Infinity (AUC [0-infinity])** _(time frame: Up to Day 29)_ — AUC (0-infinity) is defined as AUC from time 0 to infinity, calculated as the sum of AUC (0-last) and C(last)/lambda(z); where C(last) is the last observed measurable (non-BQL) concentration; and lambda(z) is apparent terminal elimination rate constant. - **Total Apparent Oral Clearance (CL/F)** _(time frame: Up to Day 29)_ — CL/F is defined as total apparent oral clearance, calculated as dose/AUC (0-infinity). - **Apparent Volume of Distribution (Vd/F)** _(time frame: Up to Day 29)_ — Vd/F is defined as apparent volume of distribution, calculated as dose/\[lambda (z)\*AUC (0-infinity)\]. - **Apparent Terminal Elimination Rate Constant (Lambda[z])** _(time frame: Up to Day 29)_ — Lambda(z) is defined as apparent terminal elimination rate constant, estimated by linear regression using the terminal log-linear phase of the log-transformed concentration vs time curve. - **Apparent Terminal Elimination Half-life (t1/2)** _(time frame: Up to Day 29)_ — t1/2 is defined as apparent terminal elimination half-life, calculated as 0.693/lambda(z). - **Percentage of JNJ-56136379 Excreted in Urine (Ae,%Dose)** _(time frame: Up to Day 7)_ — Ae,%Dose is defined as cumulative urinary recovery represented as a percentage of dose, calculated as 100\*(Aetotal/Dose). - **Renal Clearance (CLr)** _(time frame: Up to 144 hours postdose)_ — CLr is defined as renal clearance, calculated as Ae(0-144h)/AUC(144h). ## Secondary Outcomes - **Number of Participants with Adverse Events as a Measure of Safety and Tolerability** _(time frame: Up to 8 weeks)_ ## Locations (2) - Orlando Clinical Research Center, Orlando, Florida, United States - The Texas Liver Institute, San Antonio, Texas, United States ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.whyStopped` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.orlando clinical research center|orlando|florida|united states` — added _(2026-05-12)_ - `locations.the texas liver institute|san antonio|texas|united states` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT04474210.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT04474210* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*